These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26161387)

  • 1. NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma.
    Fionda C; Soriani A; Zingoni A; Santoni A; Cippitelli M
    Biomed Res Int; 2015; 2015():178698. PubMed ID: 26161387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy using NKG2D and DNAM-1 systems.
    Morisaki T; Onishi H; Katano M
    Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.
    Niu C; Jin H; Li M; Zhu S; Zhou L; Jin F; Zhou Y; Xu D; Xu J; Zhao L; Hao S; Li W; Cui J
    Oncotarget; 2017 Jan; 8(4):5954-5964. PubMed ID: 27992381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
    Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
    Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions.
    Morgado S; Sanchez-Correa B; Casado JG; Duran E; Gayoso I; Labella F; Solana R; Tarazona R
    J Innate Immun; 2011; 3(4):365-73. PubMed ID: 21576932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
    Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
    Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
    Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
    J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of NK cell function driven by Vα24
    Iyoda T; Yamasaki S; Hidaka M; Kawano F; Abe Y; Suzuki K; Kadowaki N; Shimizu K; Fujii SI
    Clin Immunol; 2018 Feb; 187():76-84. PubMed ID: 29061445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.
    Zingoni A; Cecere F; Vulpis E; Fionda C; Molfetta R; Soriani A; Petrucci MT; Ricciardi MR; Fuerst D; Amendola MG; Mytilineos J; Cerboni C; Paolini R; Cippitelli M; Santoni A
    J Immunol; 2015 Jul; 195(2):736-48. PubMed ID: 26071561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.
    Soriani A; Iannitto ML; Ricci B; Fionda C; Malgarini G; Morrone S; Peruzzi G; Ricciardi MR; Petrucci MT; Cippitelli M; Santoni A
    J Immunol; 2014 Jul; 193(2):950-60. PubMed ID: 24913980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3.
    Fionda C; Malgarini G; Soriani A; Zingoni A; Cecere F; Iannitto ML; Ricciardi MR; Federico V; Petrucci MT; Santoni A; Cippitelli M
    J Immunol; 2013 Jun; 190(12):6662-72. PubMed ID: 23686482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
    Mamessier E; Sylvain A; Bertucci F; Castellano R; Finetti P; Houvenaeghel G; Charaffe-Jaufret E; Birnbaum D; Moretta A; Olive D
    Cancer Res; 2011 Nov; 71(21):6621-32. PubMed ID: 21937679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked.
    von Lilienfeld-Toal M; Frank S; Leyendecker C; Feyler S; Jarmin S; Morgan R; Glasmacher A; Märten A; Schmidt-Wolf IG; Brossart P; Cook G
    Cancer Immunol Immunother; 2010 Jun; 59(6):829-39. PubMed ID: 20024547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
    Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
    Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.
    Soriani A; Zingoni A; Cerboni C; Iannitto ML; Ricciardi MR; Di Gialleonardo V; Cippitelli M; Fionda C; Petrucci MT; Guarini A; Foà R; Santoni A
    Blood; 2009 Apr; 113(15):3503-11. PubMed ID: 19098271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant deletion of SLAM-family receptors, NKG2D and DNAM-1 reveals gene redundancy of NK cell activating receptors in NK cell development and education.
    Chen S; Dong Z
    J Leukoc Biol; 2020 Apr; 107(4):561-572. PubMed ID: 31729776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.